Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Open-Label PK Study of Olomorasib Capsule Formulations and Food Effect in Healthy Japanese Participants
jRCT2051250107Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olomorasib (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Cmax of Olomorasib and AUC(0-tlast) of Olomorasib. Started Sep 2025; status: completed.
02
Drugs
olomorasib
Beyond the preview
Go deeper on jRCT2051250107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250107.